6 resultater
FIELD OF THE DISCLOSURE
The present disclosure relates to compositions and methods for the treatment of disorders associated with neuronal degeneration. More specifically, the present disclosure relates to of a mutant form of erythropoietin (EPO) for the treatment of disorders associated with
FIELD OF THE DISCLOSURE
The present disclosure relates to compositions and methods for the treatment of disorders associated with neuronal degeneration. More specifically, the present disclosure relates to of a mutant form of erythropoietin (EPO) for the treatment of disorders associated with
SEQUENCE LISTING
This application contains a Sequence Listing submitted electronically as a text file by EFS-Web. The text file, named "6837-1 Sequence Listing ST25", has a size in bytes of 4 KB, and was recorded on Jun. 13, 2013. The information contained in the text file is incorporated herein by
FIELD OF INVENTION
The present invention generally relates to methods, compositions and materials for treatment and prevention of axonal and neuronal degeneration and related nerve injury, toxic insults or neurodegenerative disorders.
BACKGROUND OF THE INVENTION
Neurodegenerative disorders are
CROSS-REFERENCE TO RELATED APPLICATIONS
This patent application is the U.S. national phase of International Patent Application No. PCT/JP2007/069433, which was filed on Oct. 4, 2007, and which claims priority to Japanese Patent Application No. 272668/2006, filed on Oct. 4, 2006.
TECHNICAL FIELD
The
FIELD OF THE INVENTION
The field relates to the use of novel nanoparticle formulations and chemical structures that include vasodilator Factor VIIa inhibitors to treat vascular disorders in a subject.
BACKGROUND OF THE INVENTION
Vascular endothelial-mediated disorders including sickle cell diseases,